PILA PHARMA
1.21 SEK
-0.49 %
Less than 1K followers
PILA
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Valuation
Income statement
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for PILA PHARMA
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 0.3 | 0.7 | 1.9 | 1.5 | 0.8 | 1.1 | |
| growth-% | 161.5 % | -22.3 % | -46.6 % | 44.9 % | |||
| EBITDA | -4.7 | -3.4 | -9.2 | -8.9 | -5.3 | -7.0 | -6.8 |
| EBIT | -4.7 | -3.4 | -9.3 | -8.9 | -6.4 | -8.1 | -7.9 |
| Profit before taxes | -8.7 | -7.0 | -17.2 | -26.8 | -9.9 | -11.2 | -16.9 |
| Net income | -8.7 | -7.0 | -17.2 | -26.8 | -9.9 | -11.2 | -16.8 |
| EPS | -0.47 | -0.38 | -0.93 | -1.38 | -0.05 | -0.39 | -0.62 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | -1,357.8 % | -1,285.1 % | -471.8 % | -364.4 % | -901.3 % | -603.5 % | |
| EBIT-% | -1,363.6 % | -1,287.9 % | -472.9 % | -437.7 % | -1,039.7 % | -698.2 % | |
| ROE | -116.3 % | -204.1 % | -56.8 % | -281.0 % | -149.1 % | -213.7 % | -113.9 % |
| ROI | -109.2 % | -130.1 % | -54.1 % | -245.9 % | -117.4 % | -180.7 % | -103.8 % |